Uncover the ten most common weight loss misconceptions and pitfalls, and learn scientifically grounded practices to achieve sustainable, healthy fat loss.
Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.
Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.
The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.
This study examines the effectiveness of physician academic detailing combined with previsit patient activation to increase diabetes medication deprescribing amongst older adults, aiming to reduce hypoglycemia-related complications.
A recent study investigates auricular acupressure's effects on glycemic markers, stress, and sleep quality in older adults with Type 2 diabetes, revealing promising outcomes and potential for nursing interventions.
A study reveals diabetic peripheral neuropathy (DPN) significantly associates with cerebral small-vessel disease (SVD), indicating a predictive role for lacunar stroke in diabetic patients and highlighting opportunities for early intervention.
This article reviews a study examining the effects of aerobic versus resistance exercise execution order on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, emphasizing clinical implications.
This study explores the effects of different exercise orders on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, highlighting some insights for clinical practice.
A study identified a robust plasma multi-metabolite signature that predicts long-term all-cause mortality in participants from the PREDIMED trial and several US cohorts, providing new insights into metabolic biomarkers.